Article Information
History
- March 28, 2021.
Article Versions
- Version 1 (March 3, 2021 - 05:06).
- Version 2 (March 4, 2021 - 08:42).
- Version 3 (March 27, 2021 - 22:48).
- You are viewing Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- José Castela Forte1,2,*,
- Pytrik Folkertsma2,3,
- Rahul Gannamani2,4,
- Sridhar Kumaraswamy2,
- Sarah Mount2,
- Tom J. de Koning4,5,
- Sipko van Dam2,3 and
- Bruce H. R. Wolffenbuttel3
- 1Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, the Netherlands
- 2Ancora Health B.V., Groningen, The Netherlands
- 3Department of Endocrinology, University of Groningen, University Medical Center Groningen, the Netherlands
- 4Department of Neurology, University of Groningen, University Medical Center Groningen, the Netherlands
- 5Pediatrics, Department of Clinical Sciences, Lund University, Lund, Sweden
- ↵*Correspondence:
José Castela Forte, BSc (Hon), Department of Pharmacy and Pharmacology, Hanzeplein 1, P.O. Box 30.001, 9700 RB Groningen, The Netherlands, Phone: +31628218360, E-mail: j.n.alves.castela.cardoso.forte{at}umcg.nl
Posted March 28, 2021.
Development and validation of decision rules models to stratify coronary artery disease, diabetes, and hypertension risk in preventive care: cohort study of returning UK Biobank participants
